Advanced Search

Project: Screening for Hepatitis C Virus Infection in Adolescents and Adults: A Systematic Review Update for the U.S. Preventive Services Task Force [Entered Retrospectively]

Public Report Complete



Project Summary

Title and Description


Key Questions


Associated Extraction Forms

Title Created by Key Questions Addressed Form Notes
Key Questions 1-9 Sara Grusing 1, 2, 3, 4, 5, 6, 7, 8, 9


Associated Studies (each link opens a new tab)

Title Author Year
Comparison of current US risk strategy to screen for hepatitis C virus with a hypothetical targeted birth cohort strategy. Tomaszewski KJ., Deniz B., Tomanovich P., Graham CS. 2012
Vertical transmission of hepatitis C virus in a cohort of 2,447 HIV-seronegative pregnant women: a 24-month prospective study. Ceci O., Margiotta M., Marello F., Francavilla R., Loizzi P., Francavilla A., Mautone A., Impedovo L., Ierardi E., Mastroianni M., Bettocchi S., Selvaggi L. 2001
Mother-to-child transmission of hepatitis C virus: evidence for preventable peripartum transmission. Gibb DM., Goodall RL., Dunn DT., Healy M., Neave P., Cafferkey M., Butler K. 2000
Risk factors for perinatal transmission of hepatitis C virus (HCV) and the natural history of HCV infection acquired in infancy. Mast EE., Hwang LY., Seto DS., Nolte FS., Nainan OV., Wurtzel H., Alter MJ. 2005
Maternal drug use is a preeminent risk factor for mother-to-child hepatitis C virus transmission: results from a multicenter study of 1372 mother-infant pairs. Resti M., Azzari C., Galli L., Zuin G., Giacchino R., Bortolotti F., Marcellini M., Moriondo M., de Martino M., Vierucci A. 2002
A significant sex--but not elective cesarean section--effect on mother-to-child transmission of hepatitis C virus infection. Tovo 2005
Efficacy and safety of glecaprevir/pibrentasvir in patients with chronic hepatitis C virus genotype 5 or 6 infection (ENDURANCE-5,6): an open-label, multicentre, phase 3b trial. Asselah T., Lee SS., Yao BB., Nguyen T., Wong F., Mahomed A., Lim SG., Abergel A., Sasadeusz J., Gane E., Zadeikis N., Schnell G., Zhang Z., Porcalla A., Mensa FJ., Nguyen K. 2019
Efficacy and safety of 12 weeks of elbasvir ± grazoprevir ± ribavirin in participants with hepatitis C virus genotype 2, 4, 5 or 6 infection: The C-SCAPE study. Brown A., Hézode C., Zuckerman E., Foster GR., Zekry A., Roberts SK., Lahser F., Durkan C., Badshah C., Zhang B., Robertson M., Wahl J., Barr E., Haber B. 2018
Direct-Acting Antiviral Therapy for HCV Infection Is Associated With a Reduced Risk of Cardiovascular Disease Events. Butt AA., Yan P., Shuaib A., Abou-Samra AB., Shaikh OS., Freiberg MS. 2019
Paritaprevir, ritonavir, ombitasvir, and dasabuvir with and without ribavirin in people with HCV genotype 1 and recent injecting drug use or receiving opioid substitution therapy. Grebely J., Conway B., Cunningham EB., Fraser C., Moriggia A., Gane E., Stedman C., Cooper C., Castro E., Schmid P., Petoumenos K., Hajarizadeh B., Marks P., Erratt A., Dalgard O., Lacombe K., Feld JJ., Bruneau J., Daulouede JP., Powis J., Bruggmann P., Matthews GV., Kronborg I., Shaw D., Dunlop A., Hellard M., Applegate TL., Crawford S., Dore GJ. 2018
Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial. Grebely J., Dalgard O., Conway B., Cunningham EB., Bruggmann P., Hajarizadeh B., Amin J., Bruneau J., Hellard M., Litwin AH., Marks P., Quiene S., Siriragavan S., Applegate TL., Swan T., Byrne J., Lacalamita M., Dunlop A., Matthews GV., Powis J., Shaw D., Thurnheer MC., Weltman M., Kronborg I., Cooper C., Feld JJ., Fraser C., Dillon JF., Read P., Gane E., Dore GJ. 2018
The short-term incidence of hepatocellular carcinoma is not increased after hepatitis C treatment with direct-acting antivirals: An ERCHIVES study. Li DK., Ren Y., Fierer DS., Rutledge S., Shaikh OS., Lo Re V., Simon T., Abou-Samra AB., Chung RT., Butt AA. 2018
Sofosbuvir in combination with daclatasvir or simeprevir for 12 weeks in noncirrhotic subjects chronically infected with hepatitis C virus genotype 1: a randomized clinical trial. Pott-Junior H., Bricks G., Grandi G., Figueiredo Senise J., Castelo Filho A. 2019
Efficacy and safety of elbasvir/grazoprevir in participants with hepatitis C virus genotype 1, 4, or 6 infection from the Asia-Pacific region and Russia: Final results from the randomized C-CORAL study. Wei L., Jia JD., Wang FS., Niu JQ., Zhao XM., Mu S., Liang LW., Wang Z., Hwang P., Robertson MN., Ingravallo P., Asante-Appiah E., Wei B., Evans B., Hanna GJ., Talwani R., Duan ZP., Zhdanov K., Cheng PN., Tanwandee T., Nguyen VK., Heo J., Isakov V., George J. 2019
Sofosbuvir-velpatasvir for treatment of chronic hepatitis C virus infection in Asia: a single-arm, open-label, phase 3 trial. Wei L., Lim SG., Xie Q., Văn KN., Piratvisuth T., Huang Y., Wu S., Xu M., Tang H., Cheng J., Le Manh H., Gao Y., Mou Z., Sobhonslidsuk A., Dou X., Thongsawat S., Nan Y., Tan CK., Ning Q., Tee HP., Mao Y., Stamm LM., Lu S., Dvory-Sobol H., Mo H., Brainard DM., Yang YF., Dao L., Wang GQ., Tanwandee T., Hu P., Tangkijvanich P., Zhang L., Gao ZL., Lin F., Le TTP., Shang J., Gong G., Li J., Su M., Duan Z., Mohamed R., Hou JL., Jia J. 2019
Ledipasvir/sofosbuvir for treatment-naive and treatment-experienced Chinese patients with genotype 1 HCV: an open-label, phase 3b study. Wei L., Xie Q., Hou JL., Tang H., Ning Q., Cheng J., Nan Y., Zhang L., Li J., Jiang J., McNabb B., Zhang F., Camus G., Mo H., Osinusi A., Brainard DM., Gong G., Mou Z., Wu S., Wang G., Hu P., Gao Y., Jia J., Duan Z. 2018
Glecaprevir-Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection. Zeuzem S., Foster GR., Wang S., Asatryan A., Gane E., Feld JJ., Asselah T., Bourlière M., Ruane PJ., Wedemeyer H., Pol S., Flisiak R., Poordad F., Chuang WL., Stedman CA., Flamm S., Kwo P., Dore GJ., Sepulveda-Arzola G., Roberts SK., Soto-Malave R., Kaita K., Puoti M., Vierling J., Tam E., Vargas HE., Bruck R., Fuster F., Paik SW., Felizarta F., Kort J., Fu B., Liu R., Ng TI., Pilot-Matias T., Lin CW., Trinh R., Mensa FJ. 2018
Sofosbuvir and Velpatasvir Combination Improves Patient-reported Outcomes for Patients With HCV Infection, Without or With Compensated or Decompensated Cirrhosis. Younossi ZM., Stepanova M., Feld J., Zeuzem S., Sulkowski M., Foster GR., Mangia A., Charlton M., O'Leary JG., Curry MP., Nader F., Henry L., Hunt S. 2017
Improvement of health-related quality of life and work productivity in chronic hepatitis C patients with early and advanced fibrosis treated with ledipasvir and sofosbuvir. Younossi ZM., Stepanova M., Afdhal N., Kowdley KV., Zeuzem S., Henry L., Hunt SL., Marcellin P. 2015
A phase IIIb study of ledipasvir/sofosbuvir fixed-dose combination tablet in treatment-naïve and treatment-experienced Korean patients chronically infected with genotype 1 hepatitis C virus. Lim YS., Ahn SH., Lee KS., Paik SW., Lee YJ., Jeong SH., Kim JH., Yoon SK., Yim HJ., Tak WY., Han SY., Yang JC., Mo H., Garrison KL., Gao B., Knox SJ., Pang PS., Kim YJ., Byun KS., Kim YS., Heo J., Han KH. 2016
Sofosbuvir Plus Velpatasvir Combination Therapy for Treatment-Experienced Patients With Genotype 1 or 3 Hepatitis C Virus Infection: A Randomized Trial. Pianko S., Flamm SL., Shiffman ML., Kumar S., Strasser SI., Dore GJ., McNally J., Brainard DM., Han L., Doehle B., Mogalian E., McHutchison JG., Rabinovitz M., Towner WJ., Gane EJ., Stedman CA., Reddy KR., Roberts SK. 2015
Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection. Feld JJ., Jacobson IM., Hézode C., Asselah T., Ruane PJ., Gruener N., Abergel A., Mangia A., Lai CL., Chan HL., Mazzotta F., Moreno C., Yoshida E., Shafran SD., Towner WJ., Tran TT., McNally J., Osinusi A., Svarovskaia E., Zhu Y., Brainard DM., McHutchison JG., Agarwal K., Zeuzem S. 2015
Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection. Foster GR., Afdhal N., Roberts SK., Bräu N., Gane EJ., Pianko S., Lawitz E., Thompson A., Shiffman ML., Cooper C., Towner WJ., Conway B., Ruane P., Bourlière M., Asselah T., Berg T., Zeuzem S., Rosenberg W., Agarwal K., Stedman CA., Mo H., Dvory-Sobol H., Han L., Wang J., McNally J., Osinusi A., Brainard DM., McHutchison JG., Mazzotta F., Tran TT., Gordon SC., Patel K., Reau N., Mangia A., Sulkowski M. 2015
Randomized phase 3 trial of ombitasvir/paritaprevir/ritonavir for hepatitis C virus genotype 1b-infected Japanese patients with or without cirrhosis. Kumada H., Chayama K., Rodrigues L., Suzuki F., Ikeda K., Toyoda H., Sato K., Karino Y., Matsuzaki Y., Kioka K., Setze C., Pilot-Matias T., Patwardhan M., Vilchez RA., Burroughs M., Redman R. 2015
Sofosbuvir With Velpatasvir in Treatment-Naive Noncirrhotic Patients With Genotype 1 to 6 Hepatitis C Virus Infection: A Randomized Trial. Everson GT., Towner WJ., Davis MN., Wyles DL., Nahass RG., Thuluvath PJ., Etzkorn K., Hinestrosa F., Tong M., Rabinovitz M., McNally J., Brainard DM., Han L., Doehle B., McHutchison JG., Morgan T., Chung RT., Tran TT. 2015
Efficacy and safety of ombitasvir/paritaprevir/r and dasabuvir compared to IFN-containing regimens in genotype 1 HCV patients: The MALACHITE-I/II trials. Dore GJ., Conway B., Luo Y., Janczewska E., Knysz B., Liu Y., Streinu-Cercel A., Caruntu FA., Curescu M., Skoien R., Ghesquiere W., Mazur W., Soza A., Fuster F., Greenbloom S., Motoc A., Arama V., Shaw D., Tornai I., Sasadeusz J., Dalgard O., Sullivan D., Liu X., Kapoor M., Campbell A., Podsadecki T. 2016
Efficacy of ledipasvir and sofosbuvir, with or without ribavirin, for 12 weeks in patients with HCV genotype 3 or 6 infection. Gane EJ., Hyland RH., An D., Svarovskaia E., Pang PS., Brainard D., Stedman CA. 2015
Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. Sulkowski MS., Gardiner DF., Rodriguez-Torres M., Reddy KR., Hassanein T., Jacobson I., Lawitz E., Lok AS., Hinestrosa F., Thuluvath PJ., Schwartz H., Nelson DR., Everson GT., Eley T., Wind-Rotolo M., Huang SP., Gao M., Hernandez D., McPhee F., Sherman D., Hindes R., Symonds W., Pasquinelli C., Grasela DM. 2014
Ombitasvir, paritaprevir, and ritonavir plus ribavirin for chronic hepatitis C virus genotype 4 infection in Egyptian patients with or without compensated cirrhosis (AGATE-II): a multicentre, phase 3, partly randomised open-label trial. Waked I., Shiha G., Qaqish RB., Esmat G., Yosry A., Hassany M., Soliman R., Mohey MA., Allam N., Zayed N., Asselah T., Hall C., Redman R., Mobashery N., Doss W. 2016
All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Nelson DR., Cooper JN., Lalezari JP., Lawitz E., Pockros PJ., Gitlin N., Freilich BF., Younes ZH., Harlan W., Ghalib R., Oguchi G., Thuluvath PJ., Ortiz-Lasanta G., Rabinovitz M., Bernstein D., Bennett M., Hawkins T., Ravendhran N., Sheikh AM., Varunok P., Kowdley KV., Hennicken D., McPhee F., Rana K., Hughes EA. 2015
Grazoprevir-Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection: A Randomized Trial. Zeuzem S., Ghalib R., Reddy KR., Pockros PJ., Ben Ari Z., Zhao Y., Brown DD., Wan S., DiNubile MJ., Nguyen BY., Robertson MN., Wahl J., Barr E., Butterton JR. 2015
Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial. Sulkowski M., Hezode C., Gerstoft J., Vierling JM., Mallolas J., Pol S., Kugelmas M., Murillo A., Weis N., Nahass R., Shibolet O., Serfaty L., Bourliere M., DeJesus E., Zuckerman E., Dutko F., Shaughnessy M., Hwang P., Howe AY., Wahl J., Robertson M., Barr E., Haber B. 2015
Simeprevir plus sofosbuvir (12 and 8 weeks) in hepatitis C virus genotype 1-infected patients without cirrhosis: OPTIMIST-1, a phase 3, randomized study. Kwo P., Gitlin N., Nahass R., Bernstein D., Etzkorn K., Rojter S., Schiff E., Davis M., Ruane P., Younes Z., Kalmeijer R., Sinha R., Peeters M., Lenz O., Fevery B., De La Rosa G., Scott J., Witek J. 2016
Efficacy and Safety of Ombitasvir, Paritaprevir, and Ritonavir in an Open-Label Study of Patients With Genotype 1b Chronic Hepatitis C Virus Infection With and Without Cirrhosis. Lawitz E., Makara M., Akarca US., Thuluvath PJ., Preotescu LL., Varunok P., Morillas RM., Hall C., Mobashery N., Redman R., Pilot-Matias T., Vilchez RA., Hézode C. 2015
Ledipasvir-sofosbuvir in patients with hepatitis C virus genotype 5 infection: an open-label, multicentre, single-arm, phase 2 study. Abergel A., Asselah T., Metivier S., Kersey K., Jiang D., Mo H., Pang PS., Samuel D., Loustaud-Ratti V. 2016
Ledipasvir plus sofosbuvir for 12 weeks in patients with hepatitis C genotype 4 infection. Abergel A., Metivier S., Samuel D., Jiang D., Kersey K., Pang PS., Svarovskaia E., Knox SJ., Loustaud-Ratti V., Asselah T. 2016
Ledipasvir/sofosbuvir fixed-dose combination tablet in Taiwanese patients with chronic genotype 1 hepatitis C virus. Chuang WL., Chien RN., Peng CY., Chang TT., Lo GH., Sheen IS., Wang HY., Chen JJ., Yang JC., Knox SJ., Gao B., Garrison KL., Mo H., Pang PS., Hsu YC., Hu TH., Chu CJ., Kao JH. 2016
The combination of elbasvir and grazoprevir for the treatment of chronic HCV infection in Japanese patients: a randomized phase II/III study. Kumada H., Suzuki Y., Karino Y., Chayama K., Kawada N., Okanoue T., Itoh Y., Mochida S., Toyoda H., Yoshiji H., Takaki S., Yatsuzuka N., Yodoya E., Iwasa T., Fujimoto G., Robertson MN., Black S., Caro L., Wahl J. 2017
Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lawitz E., Sulkowski MS., Ghalib R., Rodriguez-Torres M., Younossi ZM., Corregidor A., DeJesus E., Pearlman B., Rabinovitz M., Gitlin N., Lim JK., Pockros PJ., Scott JD., Fevery B., Lambrecht T., Ouwerkerk-Mahadevan S., Callewaert K., Symonds WT., Picchio G., Lindsay KL., Beumont M., Jacobson IM. 2014
Patient-reported outcomes in individuals with hepatitis C virus infection treated with elbasvir/grazoprevir. Ng X., Nwankwo C., Arduino JM., Corman S., Lasch KE., Lustrino JM., Patel S., Platt HL., Qiu J., Sperl J. 2018
Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study. Carrat F., Fontaine H., Dorival C., Simony M., Diallo A., Hezode C., De Ledinghen V., Larrey D., Haour G., Bronowicki JP., Zoulim F., Asselah T., Marcellin P., Thabut D., Leroy V., Tran A., Habersetzer F., Samuel D., Guyader D., Chazouilleres O., Mathurin P., Metivier S., Alric L., Riachi G., Gournay J., Abergel A., Cales P., Ganne N., Loustaud-Ratti V., D'Alteroche L., Causse X., Geist C., Minello A., Rosa I., Gelu-Simeon M., Portal I., Raffi F., Bourliere M., Pol S. 2019
Safety and efficacy of combined sofosbuvir/daclatasvir treatment of children and adolescents with chronic hepatitis C Genotype 4. Abdel Ghaffar TY., El Naghi S., Abdel Gawad M., Helmy S., Abdel Ghaffar A., Yousef M., Moafy M. 2019
Efficacy and safety of sofosbuvir-ledipasvir for treatment of a cohort of Egyptian patients with chronic hepatitis C genotype 4 infection. Ahmed OA., Kaisar HH., Badawi R., Hawash N., Samir H., Shabana SS., Fouad MHA., Rizk FH., Khodeir SA., Abd-Elsalam S. 2018
Sustained Viral Response in Genotype 4 Chronic Hepatitis C Virus-infected Children and Adolescents Treated With Sofosbuvir/Ledipasvir. El-Karaksy H., Mogahed EA., Abdullatif H., Ghobrial C., El-Raziky MS., El-Koofy N., El-Shabrawi M., Ghita H., Baroudy S., Okasha S. 2018
Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1. Kowdley KV., Lawitz E., Poordad F., Cohen DE., Nelson DR., Zeuzem S., Everson GT., Kwo P., Foster GR., Sulkowski MS., Xie W., Pilot-Matias T., Liossis G., Larsen L., Khatri A., Podsadecki T., Bernstein B. 2014
Ombitasvir/paritaprevir/r and dasabuvir plus ribavirin in HCV genotype 1-infected patients on methadone or buprenorphine. Lalezari J., Sullivan JG., Varunok P., Galen E., Kowdley KV., Rustgi V., Aguilar H., Felizarta F., McGovern B., King M., Polepally AR., Cohen DE. 2015
Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lawitz E., Sulkowski MS., Ghalib R., Rodriguez-Torres M., Younossi ZM., Corregidor A., DeJesus E., Pearlman B., Rabinovitz M., Gitlin N., Lim JK., Pockros PJ., Scott JD., Fevery B., Lambrecht T., Ouwerkerk-Mahadevan S., Callewaert K., Symonds WT., Picchio G., Lindsay KL., Beumont M., Jacobson IM. 2014
Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. Afdhal N., Zeuzem S., Kwo P., Chojkier M., Gitlin N., Puoti M., Romero-Gomez M., Zarski JP., Agarwal K., Buggisch P., Foster GR., Bräu N., Buti M., Jacobson IM., Subramanian GM., Ding X., Mo H., Yang JC., Pang PS., Symonds WT., McHutchison JG., Muir AJ., Mangia A., Marcellin P. 2014
Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. Kowdley KV., Gordon SC., Reddy KR., Rossaro L., Bernstein DE., Lawitz E., Shiffman ML., Schiff E., Ghalib R., Ryan M., Rustgi V., Chojkier M., Herring R., Di Bisceglie AM., Pockros PJ., Subramanian GM., An D., Svarovskaia E., Hyland RH., Pang PS., Symonds WT., McHutchison JG., Muir AJ., Pound D., Fried MW. 2014
Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial. Lawitz E., Poordad FF., Pang PS., Hyland RH., Ding X., Mo H., Symonds WT., McHutchison JG., Membreno FE. 2014
Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct-acting antiviral treatment. Poordad F., Felizarta F., Asatryan A., Sulkowski MS., Reindollar RW., Landis CS., Gordon SC., Flamm SL., Fried MW., Bernstein DE., Lin CW., Liu R., Lovell SS., Ng TI., Kort J., Mensa FJ. 2017
Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial. Hézode C., Asselah T., Reddy KR., Hassanein T., Berenguer M., Fleischer-Stepniewska K., Marcellin P., Hall C., Schnell G., Pilot-Matias T., Mobashery N., Redman R., Vilchez RA., Pol S. 2015
ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection. Andreone P., Colombo MG., Enejosa JV., Koksal I., Ferenci P., Maieron A., Müllhaupt B., Horsmans Y., Weiland O., Reesink HW., Rodrigues L., Hu YB., Podsadecki T., Bernstein B. 2014
ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. Ferenci P., Bernstein D., Lalezari J., Cohen D., Luo Y., Cooper C., Tam E., Marinho RT., Tsai N., Nyberg A., Box TD., Younes Z., Enayati P., Green S., Baruch Y., Bhandari BR., Caruntu FA., Sepe T., Chulanov V., Janczewska E., Rizzardini G., Gervain J., Planas R., Moreno C., Hassanein T., Xie W., King M., Podsadecki T., Reddy KR. 2014
Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. Feld JJ., Kowdley KV., Coakley E., Sigal S., Nelson DR., Crawford D., Weiland O., Aguilar H., Xiong J., Pilot-Matias T., DaSilva-Tillmann B., Larsen L., Podsadecki T., Bernstein B. 2014
Health-related Quality of Life in Adolescent Patients With Hepatitis C Genotype 1 Treated With Sofosbuvir and Ledipasvir. Younossi ZM., Stepanova M., Balistreri W., Schwarz K., Murray KF., Rosenthal P., Bansal S., Hunt S. 2018
Long-term outcome after interferon therapy in elderly patients with chronic hepatitis C. Arase Y., Ikeda K., Suzuki F., Suzuki Y., Saitoh S., Kobayashi M., Akuta N., Someya T., Koyama R., Hosaka T., Sezaki H., Kobayashi M., Kumada H. 2007
Effect of aging on risk for hepatocellular carcinoma in chronic hepatitis C virus infection. Asahina Y., Tsuchiya K., Tamaki N., Hirayama I., Tanaka T., Sato M., Yasui Y., Hosokawa T., Ueda K., Kuzuya T., Nakanishi H., Itakura J., Takahashi Y., Kurosaki M., Enomoto N., Izumi N. 2010
A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C. Backus LI., Boothroyd DB., Phillips BR., Belperio P., Halloran J., Mole LA. 2011
Effect of Paritaprevir/Ritonavir/Ombitasvir/Dasabuvir and Ledipasvir/Sofosbuvir Regimens on Survival Compared With Untreated Hepatitis C Virus-Infected Persons: Results From ERCHIVES. Butt AA., Yan P., Simon TG., Abou-Samra AB. 2017
Nonresponse to interferon-α based treatment for chronic hepatitis C infection is associated with increased hazard of cirrhosis. Cozen ML., Ryan JC., Shen H., Lerrigo R., Yee RM., Sheen E., Wu R., Monto A. 2013
All-cause mortality and liver-related outcomes following successful antiviral treatment for chronic hepatitis C. Dieperink E., Pocha C., Thuras P., Knott A., Colton S., Ho SB. 2014
The incidence and risk factors for the development of hepatocellular carcinoma after peginterferon plus ribavirin therapy for chronic hepatitis C. Dohmen K., Kawano A., Takahashi K., Shigematsu H., Tanaka H., Haruno M., Yanagita K., Ichiki Y., Mori T., Hayashida K., Shimoda S., Ishibashi H., Nomura H. -- Not Found --
Racial differences in the progression to cirrhosis and hepatocellular carcinoma in HCV-infected veterans. El-Serag HB., Kramer J., Duan Z., Kanwal F. 2014
Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: A long-term observation study of 1,643 patients using statistical bias correction with proportional hazard analysis. Ikeda K., Saitoh S., Arase Y., Chayama K., Suzuki Y., Kobayashi M., Tsubota A., Nakamura I., Murashima N., Kumada H., Kawanishi M. 1999
Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C. Osaka Hepatocellular Carcinoma Prevention Study Group. Imai Y., Kawata S., Tamura S., Yabuuchi I., Noda S., Inada M., Maeda Y., Shirai Y., Fukuzaki T., Kaji I., Ishikawa H., Matsuda Y., Nishikawa M., Seki K., Matsuzawa Y. 1998
Favorable prognosis of chronic hepatitis C after interferon therapy by long-term cohort study. Imazeki F., Yokosuka O., Fukai K., Saisho H. 2003
Excess liver-related morbidity of chronic hepatitis C patients, who achieve a sustained viral response, and are discharged from care. Innes HA., Hutchinson SJ., Allen S., Bhattacharyya D., Bramley P., Delahooke TE., Dillon JF., Forrest E., Fraser A., Gillespie R., Goldberg DJ., Kennedy N., McDonald S., McLeod A., Mills PR., Morris J., Hayes P. 2011
HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma. Ioannou GN., Green PK., Berry K. 2017
Development of hepatocellular carcinoma after interferon therapy in chronic hepatitis C. Is it possible to reduce the incidence by ribanirin and IFN combination therapy? Izumi N., Yasuhiro A., Kurosaki M., Onuki Y., Nishimura Y., Inoue K., Ueda K., Tsuchiya K., Nakanishi H., Uchihara M., Miyake S. 2005
Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Osaka Liver Disease Study Group. Kasahara A., Hayashi N., Mochizuki K., Takayanagi M., Yoshioka K., Kakumu S., Iijima A., Urushihara A., Kiyosawa K., Okuda M., Hino K., Okita K. 1998
Interferon treatment improves survival in chronic hepatitis C patients showing biochemical as well as virological responses by preventing liver-related death. Kasahara A., Tanaka H., Okanoue T., Imai Y., Tsubouchi H., Yoshioka K., Kawata S., Tanaka E., Hino K., Hayashi K., Tamura S., Itoh Y., Kiyosawa K., Kakumu S., Okita K., Hayashi N. 2004
Effect of interferon alpha-2b plus ribavirin therapy on incidence of hepatocellular carcinoma in patients with chronic hepatitis. Kurokawa M., Hiramatsu N., Oze T., Mochizuki K., Yakushijin T., Kurashige N., Inoue Y., Igura T., Imanaka K., Yamada A., Oshita M., Hagiwara H., Mita E., Ito T., Inui Y., Hijioka T., Yoshihara H., Inoue A., Imai Y., Kato M., Kiso S., Kanto T., Takehara T., Kasahara A., Hayashi N. 2009
Assessment of hepatocellular carcinoma risk based on peg-interferon plus ribavirin treatment experience in this new era of highly effective oral antiviral drugs. Lee SH., Jin YJ., Shin JY., Lee JW. 2017
Long-term cohort study of chronic hepatitis C according to interferon efficacy. Maruoka D., Imazeki F., Arai M., Kanda T., Fujiwara K., Yokosuka O. 2012
Transient biochemical response in interferon therapy decreases the development of hepatocellular carcinoma for five years and improves the long-term survival of chronic hepatitis C patients. Okanoue T., Itoh Y., Kirishima T., Daimon Y., Toyama T., Morita A., Nakajima T., Minami M. 2002
Decrease in alpha-fetoprotein levels predicts reduced incidence of hepatocellular carcinoma in patients with hepatitis C virus infection receiving interferon therapy: a single center study. Osaki Y., Ueda Y., Marusawa H., Nakajima J., Kimura T., Kita R., Nishikawa H., Saito S., Henmi S., Sakamoto A., Eso Y., Chiba T. 2012
Long-term benefit of hepatitis C therapy in a safety net hospital system: a cross-sectional study with median 5-year follow-up. Singal AG., Dharia TD., Malet PF., Alqahtani S., Zhang S., Cuthbert JA. 2013
Disease progression and the risk factor analysis for chronic hepatitis C. Sinn DH., Paik SW., Kang P., Kil JS., Park SU., Lee SY., Song SM., Gwak GY., Choi MS., Lee JH., Koh KC., Yoo BC. 2008
Effect of interferon therapy on the incidence of hepatocellular carcinoma and mortality of patients with chronic hepatitis C: a retrospective cohort study of 738 patients. Tanaka H., Tsukuma H., Kasahara A., Hayashi N., Yoshihara H., Masuzawa M., Kanda T., Kashiwagi T., Inoue A., Kato M., Oshima A., Kinoshita Y., Kamada T. 2000
Alpha-fetoprotein above normal levels as a risk factor for the development of hepatocellular carcinoma in patients infected with hepatitis C virus. Tateyama M., Yatsuhashi H., Taura N., Motoyoshi Y., Nagaoka S., Yanagi K., Abiru S., Yano K., Komori A., Migita K., Nakamura M., Nagahama H., Sasaki Y., Miyakawa Y., Ishibashi H. 2011
Association of sustained virologic response with reduced progression to liver cirrhosis in elderly patients with chronic hepatitis C. Tseng CW., Chang TT., Tzeng SJ., Hsieh YH., Hung TH., Huang HT., Wu SF., Tseng KC. 2016
Interferon therapy prolonged life expectancy among chronic hepatitis C patients. Yoshida H., Arakawa Y., Sata M., Nishiguchi S., Yano M., Fujiyama S., Yamada G., Yokosuka O., Shiratori Y., Omata M. 2002
Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy. Yoshida H., Shiratori Y., Moriyama M., Arakawa Y., Ide T., Sata M., Inoue O., Yano M., Tanaka M., Fujiyama S., Nishiguchi S., Kuroki T., Imazeki F., Yokosuka O., Kinoyama S., Yamada G., Omata M. 1999
A sustained virological response to interferon or interferon/ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C: a nationwide, multicentre study in Taiwan. Yu ML., Lin SM., Chuang WL., Dai CY., Wang JH., Lu SN., Sheen IS., Chang WY., Lee CM., Liaw YF. 2006
Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Adolescents With Chronic Hepatitis C Virus: Part 1 of the DORA Study. Jonas MM., Squires RH., Rhee SM., Lin CW., Bessho K., Feiterna-Sperling C., Hierro L., Kelly D., Ling SC., Strokova T., Del Valle-Segarra A., Lovell S., Liu W., Ng TI., Porcalla A., Gonzalez YS., Burroughs M., Sokal E. 2020
Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2, 4, 5, or 6 Infection Without Cirrhosis. Asselah T., Kowdley KV., Zadeikis N., Wang S., Hassanein T., Horsmans Y., Colombo M., Calinas F., Aguilar H., de Ledinghen V., Mantry PS., Hezode C., Marinho RT., Agarwal K., Nevens F., Elkhashab M., Kort J., Liu R., Ng TI., Krishnan P., Lin CW., Mensa FJ. 2018
Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 1 hepatitis C virus infection with and without cirrhosis. Chayama K., Suzuki F., Karino Y., Kawakami Y., Sato K., Atarashi T., Naganuma A., Watanabe T., Eguchi Y., Yoshiji H., Seike M., Takei Y., Kato K., Alves K., Burroughs M., Redman R., Pugatch DL., Pilot-Matias TJ., Krishnan P., Oberoi RK., Xie W., Kumada H. 2018
Efficacy and safety of elbasvir/grazoprevir and sofosbuvir/pegylated interferon/ribavirin: A phase III randomized controlled trial. Sperl J., Horvath G., Halota W., Ruiz-Tapiador JA., Streinu-Cercel A., Jancoriene L., Werling K., Kileng H., Koklu S., Gerstoft J., Urbanek P., Flisiak R., Leiva R., Kazenaite E., Prinzing R., Patel S., Qiu J., Asante-Appiah E., Wahl J., Nguyen BY., Barr E., Platt HL. 2016
Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 2 hepatitis C virus infection. Toyoda H., Chayama K., Suzuki F., Sato K., Atarashi T., Watanabe T., Atsukawa M., Naganuma A., Notsumata K., Osaki Y., Nakamuta M., Takaguchi K., Saito S., Kato K., Pugatch D., Burroughs M., Redman R., Alves K., Pilot-Matias TJ., Oberoi RK., Fu B., Kumada H. 2018
The safety and effectiveness of ledipasvir-sofosbuvir in adolescents 12-17 years old with hepatitis C virus genotype 1 infection. Balistreri WF., Murray KF., Rosenthal P., Bansal S., Lin CH., Kersey K., Massetto B., Zhu Y., Kanwar B., German P., Svarovskaia E., Brainard DM., Wen J., Gonzalez-Peralta RP., Jonas MM., Schwarz K. 2017
Sofosbuvir and ribavirin in adolescents 12-17 years old with hepatitis C virus genotype 2 or 3 infection. Wirth S., Rosenthal P., Gonzalez-Peralta RP., Jonas MM., Balistreri WF., Lin CH., Hardikar W., Kersey K., Massetto B., Kanwar B., Brainard DM., Shao J., Svarovskaia E., Kirby B., Arnon R., Murray KF., Schwarz KB. 2017
Dual Sofosbuvir/Daclatasvir Therapy in Adolescent Patients With Chronic Hepatitis C Infection. Yakoot M., El-Shabrawi MH., AbdElgawad MM., Mahfouz AA., Helmy S., Abdo AM., El-Khayat HR. 2018
Ombitasvir/Paritaprevir/Ritonavir With or Without Dasabuvir and With or Without Ribavirin for Adolescents With HCV Genotype 1 or 4. Leung DH., Wirth S., Yao BB., Viani RM., Gonzalez-Peralta RP., Jonas MM., Lobritto SJ., Narkewicz MR., Sokal E., Fortuny C., Hsu EK., Del Valle-Segarra A., Zha J., Larsen L., Liu L., Shuster DL., Cohen DE., Rosenthal P. 2018




Creative Commons LicenseThis graphic notice indicates that you are leaving this Federal Government Web site and entering a non-Federal Web site. Creative Commons  
The data contained in this project are distributed under the terms of the Creative Commons Attribution-NonCommerical license, which permits the use, dissemination, and reproduction in any medium, provided the original work is properly cited, and that the use is non-commercial and otherwise in compliance with the license. See: https://creativecommons.org/licenses/by-nc/3.0/